SG162760A1 - Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b - Google Patents
Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-bInfo
- Publication number
- SG162760A1 SG162760A1 SG201003976-6A SG2010039766A SG162760A1 SG 162760 A1 SG162760 A1 SG 162760A1 SG 2010039766 A SG2010039766 A SG 2010039766A SG 162760 A1 SG162760 A1 SG 162760A1
- Authority
- SG
- Singapore
- Prior art keywords
- domain
- antibody
- cdr2
- cdr3
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50188103P | 2003-09-10 | 2003-09-10 | |
| EP03255633A EP1514561A1 (en) | 2003-09-10 | 2003-09-10 | Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG162760A1 true SG162760A1 (en) | 2010-07-29 |
Family
ID=34130349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG201003976-6A SG162760A1 (en) | 2003-09-10 | 2004-09-01 | Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20050074401A1 (zh) |
| EP (3) | EP1514561A1 (zh) |
| JP (1) | JP2007505065A (zh) |
| KR (1) | KR101129161B1 (zh) |
| CN (1) | CN100482285C (zh) |
| AT (1) | ATE499949T1 (zh) |
| AU (2) | AU2004269897B2 (zh) |
| BR (1) | BRPI0414272A (zh) |
| CA (1) | CA2536256C (zh) |
| CR (2) | CR8331A (zh) |
| DE (1) | DE602004031635D1 (zh) |
| DK (1) | DK1663320T3 (zh) |
| EA (1) | EA010653B1 (zh) |
| EC (1) | ECSP066499A (zh) |
| ES (1) | ES2361743T3 (zh) |
| HK (1) | HK1092375A1 (zh) |
| IL (1) | IL173560A0 (zh) |
| ME (1) | MEP13108A (zh) |
| NO (1) | NO20061619L (zh) |
| NZ (1) | NZ545640A (zh) |
| PL (1) | PL1663320T3 (zh) |
| PT (1) | PT1663320E (zh) |
| RS (1) | RS20060176A (zh) |
| SG (1) | SG162760A1 (zh) |
| SI (1) | SI1663320T1 (zh) |
| UA (1) | UA89759C2 (zh) |
| WO (1) | WO2005023318A1 (zh) |
| ZA (1) | ZA200602014B (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1259548A1 (en) * | 2000-02-24 | 2002-11-27 | Eidgenössische Technische Hochschule Zürich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
| ATE452912T1 (de) * | 2002-03-11 | 2010-01-15 | Philogen Spa | Antikörper aus anti-ed-b l19 gerichtet auf tumorblutgefässe |
| US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| ATE548052T1 (de) * | 2008-01-17 | 2012-03-15 | Philogen Spa | Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler |
| LT2281006T (lt) | 2008-04-30 | 2017-11-27 | Immunogen, Inc. | Skersinių jungčių linkeriai ir jų panaudojimas |
| AU2015202204A1 (en) * | 2008-04-30 | 2015-05-14 | Immunogen, Inc. | Cross-linkers and their uses |
| WO2011147762A2 (en) * | 2010-05-25 | 2011-12-01 | Bayer Pharma Aktiengesellschaft | Stabilized radiopharmaceutical composition |
| US10611830B2 (en) * | 2013-06-06 | 2020-04-07 | Hefei Lifeon Pharmaceutical Co. Ltd. | Human antibody against ED-B domain of fibronectin and uses thereof |
| GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| US10517238B2 (en) | 2017-09-18 | 2019-12-31 | Deere & Company | Implement optimization by automated adjustments |
| WO2020249757A1 (en) | 2019-06-14 | 2020-12-17 | Philogen S.P.A | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha |
| EP4153232B1 (en) | 2020-05-22 | 2024-06-26 | Philogen S.p.A. | Tnf-a immunoconjugate therapy for the treatment of brain tumors |
| CN111808161A (zh) * | 2020-06-01 | 2020-10-23 | 北京大学 | 一种对生物化合物进行放射性标记的方法 |
| EP4440599A1 (en) | 2022-01-04 | 2024-10-09 | Philogen S.p.A. | Combination of an immunocytokine comprising il-12 and a kinase inhibitor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US20030045681A1 (en) * | 1998-05-11 | 2003-03-06 | Anthony J. Zelano | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| ATE333900T1 (de) | 2000-02-24 | 2006-08-15 | Philogen Spa | Zusamensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen |
| EP1259548A1 (en) * | 2000-02-24 | 2002-11-27 | Eidgenössische Technische Hochschule Zürich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
| AU2001281824A1 (en) * | 2000-06-15 | 2001-12-24 | Patrizia Castellani | Methods for quantitative determination of b-fibronectin in biological fluids and tissues |
| CA2468081A1 (en) * | 2002-01-03 | 2003-07-10 | Schering Aktiengesellschaft | Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours |
| ATE452912T1 (de) * | 2002-03-11 | 2010-01-15 | Philogen Spa | Antikörper aus anti-ed-b l19 gerichtet auf tumorblutgefässe |
-
2003
- 2003-09-10 EP EP03255633A patent/EP1514561A1/en not_active Withdrawn
-
2004
- 2004-09-01 EP EP10008347A patent/EP2246070A2/en not_active Withdrawn
- 2004-09-01 NZ NZ545640A patent/NZ545640A/xx unknown
- 2004-09-01 SG SG201003976-6A patent/SG162760A1/en unknown
- 2004-09-01 DK DK04764695.5T patent/DK1663320T3/da active
- 2004-09-01 KR KR1020067004816A patent/KR101129161B1/ko not_active IP Right Cessation
- 2004-09-01 PL PL04764695T patent/PL1663320T3/pl unknown
- 2004-09-01 AU AU2004269897A patent/AU2004269897B2/en not_active Ceased
- 2004-09-01 JP JP2006525703A patent/JP2007505065A/ja active Pending
- 2004-09-01 EA EA200600494A patent/EA010653B1/ru not_active IP Right Cessation
- 2004-09-01 RS YUP-2006/0176A patent/RS20060176A/sr unknown
- 2004-09-01 ES ES04764695T patent/ES2361743T3/es not_active Expired - Lifetime
- 2004-09-01 AT AT04764695T patent/ATE499949T1/de active
- 2004-09-01 CA CA2536256A patent/CA2536256C/en not_active Expired - Fee Related
- 2004-09-01 EP EP04764695A patent/EP1663320B1/en not_active Expired - Lifetime
- 2004-09-01 PT PT04764695T patent/PT1663320E/pt unknown
- 2004-09-01 CN CNB2004800260484A patent/CN100482285C/zh not_active Expired - Fee Related
- 2004-09-01 ME MEP-131/08A patent/MEP13108A/xx unknown
- 2004-09-01 UA UAA200603803A patent/UA89759C2/ru unknown
- 2004-09-01 DE DE602004031635T patent/DE602004031635D1/de not_active Expired - Lifetime
- 2004-09-01 WO PCT/EP2004/009733 patent/WO2005023318A1/en active Application Filing
- 2004-09-01 SI SI200431651T patent/SI1663320T1/sl unknown
- 2004-09-01 BR BRPI0414272-1A patent/BRPI0414272A/pt not_active IP Right Cessation
- 2004-09-10 US US10/937,882 patent/US20050074401A1/en not_active Abandoned
-
2006
- 2006-02-06 IL IL173560A patent/IL173560A0/en unknown
- 2006-03-09 ZA ZA200602014A patent/ZA200602014B/en unknown
- 2006-04-06 CR CR8331A patent/CR8331A/es unknown
- 2006-04-10 NO NO20061619A patent/NO20061619L/no not_active Application Discontinuation
- 2006-04-10 EC EC2006006499A patent/ECSP066499A/es unknown
- 2006-11-30 HK HK06113130.8A patent/HK1092375A1/xx not_active IP Right Cessation
-
2009
- 2009-01-08 US US12/350,346 patent/US20090214423A1/en not_active Abandoned
-
2010
- 2010-01-22 AU AU2010200271A patent/AU2010200271A1/en not_active Abandoned
-
2011
- 2011-03-24 CR CR20110168A patent/CR20110168A/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL173560A0 (en) | Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b | |
| CN109963591A (zh) | B7h3抗体-药物偶联物及其医药用途 | |
| Tang et al. | Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments | |
| AU2023233096A1 (en) | Anti-TIGIT antibodies and uses thereof | |
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
| JP2024069225A (ja) | 標的分子に対する抗原結合コンストラクト | |
| WO2006089133A3 (en) | Anti-cd19 antibodies and uses in oncology | |
| Mersmann et al. | Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas | |
| SG155883A1 (en) | Anti-cd3 antibodies and methods of use thereof | |
| WO2006133450A3 (en) | Anti-cd19 antibody therapy for the transplantation | |
| KR20170036142A (ko) | 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법 | |
| WO2007062245A3 (en) | Human monoclonal antibody human cd134 (ox40) and methods of making and using same | |
| WO2006121852A3 (en) | Anti-cd19 antibody therapy for autoimmune disease | |
| RS54393B1 (en) | HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR | |
| PE20091269A1 (es) | Moleculas de union al receptor ox40 humano | |
| WO2006055778A3 (en) | Immunoglobulin variable region cassette exchange | |
| TW200720289A (en) | Antibodies against CCR5 and uses thereof | |
| HRP20110758T1 (en) | Il-17 antagonistic antibodies | |
| TNSN06087A1 (en) | Therapeutic binding molecules | |
| WO2007120693A3 (en) | Targeted binding agents directed to upar and uses thereof | |
| ECSP034714A (es) | Moleculas de enlace terapeuticas | |
| WO2004094473A3 (en) | Humanized antibodies to interferon alpha receptor-1 (ifnar-1) | |
| KR20210148228A (ko) | 항-EGFRvIII 항체 및 그의 항원-결합 단편 | |
| NZ593171A (en) | Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent |